Pioneering affordable virotherapy from India, for the world.
Founded in Bangalore, Neovira Therapeutics is among the first companies in India focused on oncolytic virotherapy innovation. Our viruses are engineered to selectively target and destroy cancer cells, transforming one of medicine’s greatest challenges into a new frontier of treatment.
Market Opportunity
Cancer immunotherapy is growing rapidly in India
Valued at USD 3.3 billion in 2023, the sector is expected to nearly triple by 2030, powered by demand for innovative treatments. Yet within this evolving market, oncolytic virotherapy remains in its infancy in India, with very few efforts advancing toward clinical translation.
Access to such therapies in India also remains limited.
Current treatment costs are estimated at USD 3,000 to 12,000 per session, depending on the cancer type and facility. By contrast, globally available oncolytic virotherapies are priced far higher, often exceeding USD 60,000 per course, highlighting both the affordability challenge and the opportunity for locally manufactured solutions.
Neovira Therapeutics is uniquely positioned to change this.
By building local manufacturing capacity and advancing affordable, home- grown virotherapies, we aim to make advanced cancer treatments accessible to Indian patients, while unlocking export opportunities to Asia and the Middle East.